Juniper Pharmaceuticals (NASDAQ: JNP) and Biolife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares Juniper Pharmaceuticals and Biolife Solutions’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Juniper Pharmaceuticals $49.98 million 2.64 -$2.06 million ($0.18) -66.67
Biolife Solutions $11.02 million 6.89 -$2.51 million ($0.21) -25.62

Juniper Pharmaceuticals has higher revenue and earnings than Biolife Solutions. Juniper Pharmaceuticals is trading at a lower price-to-earnings ratio than Biolife Solutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Juniper Pharmaceuticals and Biolife Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals -4.12% -3.91% -2.62%
Biolife Solutions -22.82% -37.37% -26.41%

Institutional & Insider Ownership

39.2% of Juniper Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.1% of Biolife Solutions shares are owned by institutional investors. 7.2% of Juniper Pharmaceuticals shares are owned by insiders. Comparatively, 36.8% of Biolife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Juniper Pharmaceuticals and Biolife Solutions, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 1 2 0 2.67
Biolife Solutions 0 0 3 0 3.00

Juniper Pharmaceuticals presently has a consensus price target of $29.00, indicating a potential upside of 141.67%. Biolife Solutions has a consensus price target of $6.50, indicating a potential upside of 20.82%. Given Juniper Pharmaceuticals’ higher probable upside, equities analysts clearly believe Juniper Pharmaceuticals is more favorable than Biolife Solutions.

Risk and Volatility

Juniper Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Biolife Solutions has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Summary

Juniper Pharmaceuticals beats Biolife Solutions on 9 of the 14 factors compared between the two stocks.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

About Biolife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; contract aseptic manufacturing formulation, fill, and finish services of liquid media products; and precision thermal packaging products and cloud-hosted Web applications. It markets its products to the regenerative medicine, bio-banking, drug discovery markets, comprising hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.